Status:

UNKNOWN

Once Daily 3TC, Efavirenz and ddI for HIV Infection

Lead Sponsor:

407 Doctors

Collaborating Sponsors:

Bristol-Myers Squibb

Merck Sharp & Dohme LLC

Conditions:

HIV Infection

AIDS

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

Poor compliance is thought to be a major cause of treatment failure. The TEddI study is a randomised, multi-centre, open-label study in well-controlled treatment-experienced HIV-infected patients to a...

Detailed Description

Rationale: 'TEddI' will enable a once-daily treatment strategy to be studied and provide information on effectiveness, patient adherence and quality of life and the tolerability of such regimens. Hyp...

Eligibility Criteria

Inclusion

  • aged 18 years or more with laboratory evidence of HIV-1 infection
  • ability to understand and provide written informed consent to participate in the study
  • stable on current ART regimen for at least 3 months prior to screening.
  • plasma HIV-RNA less than 400 copies/ml at the screening visit.
  • women of child bearing potential must have a negative serum or urine β-HCG pregnancy test within 14 days prior to week -4 (assessment of study eligibility)

Exclusion

  • virological failure of a proposed Once daily arm medication
  • a serious medical condition which may compromise the subject's safety, including an active AIDS-defining condition within the previous 6 months
  • known toxicities to any of the proposed Once daily arm medications
  • laboratory abnormalities at screening:
  • serum creatinine greater than twice the upper limit of normal (2 x upper limit of normal (ULN))
  • AST, ALT or alkaline phosphatase greater than 5 times the ULN
  • lactate greater than 2.5 x ULN
  • haemoglobin less than 9.5 g/dL
  • women who are pregnant or breast-feeding or who, if of child-bearing potential, are not willing to use adequate contraception (including barrier contraception)
  • patients who in the investigator's opinion are unlikely to complete the study

Key Trial Info

Start Date :

May 1 2004

Trial Type :

INTERVENTIONAL

End Date :

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT00214435

Start Date

May 1 2004

Last Update

October 25 2005

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

407 Doctors

Sydney, New South Wales, Australia, 2010